Journal
PARASITOLOGY
Volume 145, Issue 2, Pages 219-236Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0031182017000993
Keywords
leishmaniasis; repurposing; repositioning; drug discovery
Categories
Funding
- CNPq [400894/2014-9]
- Royal Society [IC160044]
- BBSRC [BB/M024156/1]
- Biotechnology and Biological Sciences Research Council [BB/M024156/1] Funding Source: researchfish
- BBSRC [BB/M024156/1] Funding Source: UKRI
- MRC [MR/P027989/1] Funding Source: UKRI
Ask authors/readers for more resources
Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the genus Leishmania for which there is a paucity of effective viable non-toxic drugs. There are 1.3 million new cases each year causing considerable socioeconomic hardship, best measured in 2.4 million disability adjusted life years, with greatest impact on the poorest communities, which means that desperately needed new antileishmanial treatments have to be both affordable and accessible. Established medicines with cheaper and faster development times may hold the cure for this neglected tropical disease. This concept of using old drugs for new diseases may not be novel but, with the ambitious target of controlling or eradicating tropical diseases by 2020, this strategy is still an important one. In this review, we will explore the current state-of-the-art of drug repurposing strategies in the search for new treatments for leishmaniasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available